Posted on April 21, 2021
SOVOS SHIPCOMPLIANT PRESS RELEASE
(BOSTON) April 21, 2021 – Last year, the Streamlined Sales Tax (SST) agreement was amended to expand relief eligibility for thousands of direct-to-consumer shippers of alcoholic beverages to 24 Streamlined Member States. In response, today global tax software provider Sovos announced that it has updated its Sovos ShipCompliant platform, enabling eligible direct-to-consumer (DtC) shippers to enjoy the full range of benefits available to remote sellers under the latest SST agreement, including expanded audit protection and compensation for the cost of calculation and remittance services.
One of only four Certified Service Providers (CSPs) already helping remote sellers manage their sales tax obligations across many states at once, Sovos is among the first to roll out added support for the thousands of beverage alcohol companies that now qualify for SST relief.
Sovos ShipCompliant Adds Audit Protection and Cost Savings for Wine, Beer and Spirits DtC Shipments in 24 Streamlined Member States
Share Article
Qualified direct-to-consumer (DtC) shippers using Sovos ShipCompliant for sales tax compliance gain new benefits in 24 Streamlined States
“Now, using our fully-approved CSP platform to ship their goods into Streamlined states, sales tax compliance is one less headache alcohol producers have to worry about,” said Larry Cormier, vice president, general manager, Sovos ShipCompliant. BOSTON (PRWEB) April 21, 2021 Last year, the Streamlined Sales Tax (SST) agreement was amended to expand relief eligibility for thousands of direct-to-consumer shippers of alcoholic beverages to 24 Streamlined Member States. In response, today global tax software provider Sovos announced that it has updated its Sovos ShipCompliant platform, enabling eligible direct-to-consumer (DtC) shippe
Immunai Joins 10x To Scale Single Cell Genomics December 21, 2020
By Allison Proffitt
December 21, 2020 | Immunai has announced its collaboration with 10x Genomics as one of the first 10x Certified Service Providers. Immunai will leverage 10x’s robust single-cell technologies to map hundreds of cell types and states. By applying its proprietary artificial intelligence and machine learning algorithms, Immunai supports biomarker discovery and insight generation to ultimately power new therapeutic discoveries and accelerate drug development.
Immunai was started by Luis Voloch and Noam Solomon about two years, Voloch told
Bio-IT World. The goal is to “revolutionize immunology” by scaling single cell genomics, he said, both in the lab and computationally.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.